news
Scientists achieve the first stable simulations of DNA crystals
A study by researchers at the Institute for Research in Biomedicine has been the first to achieve stable simulations of DNA crystals...
List view / Grid view
DNA
news
Molecules associated with NMDAR may be involved in schizophrenia
Genetic variants which prevent a neurotransmitter receptor from working properly have been implicated in the development of schizophrenia...
news
DNA barcodes that reliably work: A game-changer for biomedical research
A new method for correcting the errors that creep into DNA barcodes has paved the way for more ambitious medical research...
article
Omics-informed drug target discovery in combating emerging infectious diseases
The catastrophic consequences of ever-increasing rates of death from infectious diseases demands new experimental strategies for drug target selection and drug design. Over the last decade, the pharmaceutical industry has been wounded by several issues including failure of drug-development programmes, burgeoning cost of drug development, increasing regulatory control, lack of…
news
T-cells engineered to recognise tumours expressing the CD30 protein marker
Researchers have genetically engineered immune cells to recognise and fight Hodgkin and non-Hodgkin lymphoma cells...
news
New tools accurately illuminates intracellular phase separation
Researchers have made discoveries about the formation of cellular components called membraneless organelles and the key role these organelles play in cells...
whitepaper
Application note: Integrated biologics – Enabling high-throughput drug discovery at Amgen with Thermo Fisher™ Platform for Science™ Software
Every day scientists are working to discover and develop new therapies and treatments to change the lives of patients suffering from serious and debilitating illnesses. Amgen Inc. has made it a priority to unlock the potential of biology to discover, develop, manufacture, and deliver innovative therapeutics to patients.
whitepaper
Application note: A complete next-generation sequencing workflow for circulating cell-free DNA isolation and analysis
Circulating cell-free DNA (cfDNA) has been shown to have potential as a noninvasive substrate for the detection and monitoring of tumour cells. As circulating tumour DNA is often present at low frequencies within cfDNA, targeted sequencing is an optimal tool for mutation detection.
news
scRNA-seq technique improves efficiency and accuracy of single cell RNA sequencing
Single nucleotide variations could be the key to better identification of tumour subpopulations...
news
Scientists pinpoint mechanism by which mutant p53 protein promotes cancer
Scientists in Australia have discovered how the most important gene in preventing cancer, TP53, is hampered in its tumour-fighting efforts by mutant p53 proteins.
news
Droplet Digital PCR detects and quantifies cancer mutation
Two ddPCR-based assays were developed to detect the two mutations in the promoter region of the TERT gene, which could be used as biomarkers...
news
Chromatin study unearths link between DNA-protein binding and cancer
A team of scientists led by Stanford University School of Medicine has identified a link between how proteins bind to our DNA and how cancer develops. This finding may allow researchers to predict cancer pathways and long-term patient outcomes.
news
GFAP gene mutation creates tangles in brain cells – cause of neurological disease
A recent study in the U.S. has identified how a mutation in the GFAP gene, which encodes for the GFAP protein, causes the tangles in brain cells associated with Alexander disease and may also impact other neurological diseases.
news
Protein sequencing method could transform biological research
A team of researchers have demonstrated a new way to sequence proteins that are much more sensitive than existing technology, identifying individual protein molecules rather than requiring millions of molecules at a time
news
Novel DNA vaccine offers broad protection against Influenza-A H3N
Researchers developed a novel DNA influenza vaccine based on four micro-consensus antigenic regions selected to represent the diversity of seasonal H3N2 viruses...
